Palvella Therapeutics Reports Top-Line Results from Pivotal Phase 2/3 VALO Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel in Patients with Pachyonychia Congenita

~ VALO Study Misses Primary Endpoint in Phase 3 Randomized Withdrawal Portion ~
~ VALO Study Achieves Primary Endpoint in Phase 2 Open-Label Portion ~
~ Palvella Plans to Share Results with the U.S. Food and Drug Administration in the First Quarter of 2021 ~

See more here